Study to Assess Safety and Activity of Combination Therapy of VRC07-523LS and Vorinostat on HIV-infected Persons
NCT03803605
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
15
Enrollment
OTHER
Sponsor class
Conditions
HIV-1 Infection
Interventions
BIOLOGICAL:
VRC07-523LS
DRUG:
Vorinostat (VOR)
Sponsor
University of North Carolina, Chapel Hill
Collaborators
[object Object]